Chemomab Therapeutics (CMMB) Stock Price, Quote, News & History | Benzinga

SPY771.59+0.26%QQQ726.36−0.36%BTC/USD82,367.42+0.98%DIA521.09+1.06%GLD380.65+1.24%TLT80.11+1.55%

Chemomab Therapeutics Ltd (CMMB) Stock Price, Quote, News & History

CMMBNASDAQ

Trade with Public

Trade with Public

$1.26

-0.025-1.94%

Last update: Oct 15, 11:40 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.29

Close

-

Volume / Avg.

6.64K / 108.80K

Day Range

$1.26 - $1.26

52 Wk Range

1.05 - 3.50

Market Cap

$9.09M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

27

Short Interest

0.15%

Days to Cover

1

Recent Chemomab Therapeutics Ltd News

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

Vandana Singh

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Vandana Singh

Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-8.73M

Investing Cash Flow (TTM)

3.22M

Financing Cash Flow (TTM)

5.91M

Free Cash Flow (TTM)

-8.74M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

403.00K

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$913.32K

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.09

Earnings Yield % (TTM)

-74.42%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.19

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$6.00M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-